Chat with Client Services
Site Search
Featured New Tests
Next Generation Sequencing
ARUP NGS testing is performed with the patient in mind. Each and every case is carefully reviewed by a Variant Scientist and Medical Director to ensure the report is custom tailored to the patient with the most cutting edge clinical information available.
Next Generation Sequencing Test Offerings
Prostate Health Index: A More Precise Cancer Screening Test
This FDA-approved test for prostate cancer screening is a multi-analyte blood test that improves the interpretation of an elevated PSA level.
Using an algorithm that calculates the results of three tests into one score, the results provide a more accurate diagnostic evaluation for determining which patients should proceed to biopsy.
Is biopsy the next step? Find out with Prostate Health Index
| 3000134 | Prostate Health Index |
- Recommended in the National Comprehensive Cancer Network (NCCN) guidelines for prostate cancer early detection.
- In a multicenter study of men with PSA levels between 4 and 10 ng/mL, the Prostate Health Index test was shown to outperform free and total PSA for prostate cancer detection.1
- New York State Department of Health approved.
Clinical References
1 Loeb S, Catalona WJ: The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol 2014 Apr;6(2):74-77.
Secondary Diagnostic For Generalized or Ocular Myasthenia Gravis
Designed for patients with generalized or ocular myasthenia gravis and no detectable antibodies to acetylcholine receptor (AChR).
| 3001576 | Muscle-Specific Kinase (MuSK) Antibody, IgG |
This secondary diagnostic test can help clinicians guide treatment, as decreasing antibody levels may be associated with therapeutic response. A negative test result does not rule out a diagnosis of myasthenia gravis.
Diagnosing CNS Demyelinating Disease or Autoimmune Encephalitis
Useful for initial evaluation of inflammatory CNS demyelinating disease, including neuromyelitis optica spectrum disorder (NMOSD) and NMOSD-like disorders, or autoimmune encephalitis.
| 3001277 | Myelin Oligodendrocyte Glycoprotein (MOG) Antibody, IgG by IFA with Reflex to Titer, Serum | |
| 3001283 | Autoimmune CNS Demyelinating Disease Reflexive Panel |
The presence of myelin oligodendrocyte glycoprotein (MOG) antibody may be associated with neuromyelitis optica spectrum disorders, including optic neuritis and transverse myelitis, brainstem encephalitis, and acute disseminated encephalomyelitis.
This test may be used in monitoring antibody persistence or treatment response in individuals who are antibody positive.
New Oncology Tests: Lymphomas and IHC Stains
Lymphomas
| 3001568 | IRF4/DUSP22 (6p25) Gene Rearrangement by FISH |
IHC Stains
Used to detect IRF4/DUSP22 rearrangements that can contribute to diagnosis and prognosis in B-cell and T-cell lymphomas.
| 3001697 | Carbonic Anhydrase IX |
| 3001704 | Treponema Pallidum |
| 3001562 | SOX-10 |
| 3001416 | Fumarate Hydratase |
Updated Pharmacogenetic Tests
Pharmacogenetic testing assesses the risk of abnormal drug metabolism for medications metabolized in specific metabolic pathways.
ARUP has updated our pharmacogenetic tests with new medically relevant genes and variants in our panels.
| 3001524 | Cytochrome P450 Genotyping Panel |
| 3001513 | CYP2D6 |
| 3001508 | CYP2C19 |
| 3001501 | CYP2C8 and CYP2C9 |
| 3001518 | CYP3A4 and CYP3A5 |
| 3001535 | TPMT and NUDT15 |
| 3001541 | Warfarin Sensitivity (CYP2C8, CYP2C9, CYP4F2, VKORC1) Genotyping |
Pharmacogenetic testing provides an opportunity to lower the cost of adverse drug events by:
- Preventing many adverse drug events before they occur.
- Reducing pharmacy costs for clients by optimizing dosage.
- Decreasing the number of patient hospitalizations.
- Improving patient compliance with their drug therapies.
